EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors

Amy Dunn, Yesim Dargaud, Yasmina Abajas iD, Manuel Carcao iD, Giancarlo Castaman iD, Adam Giermasz, Cédric Hermans, Victor Jiménez-Yuste iD, Magdalena Lewandowska iD, Johnny Mahlangu iD, Shannon Meeks iD, Wolfgang Miesbach iD und 7 weitere

Haemophilia · 2025

DOI: 10.1111/hae.15109 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Haemophilia, 2025. Verfasst von Amy Dunn und 18 weiteren Autor:innen. Beteiligte Einrichtung: Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Hemophilia A, Hemorrhage, Factor VIIa, Hemophilia B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Eptacog beta is a novel human recombinant FVIIa approved for use in the United States, European Union, United Kingdom and Mexico for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors (≥12 years). It is also indicated for perioperative care in the same patient population in Europe and the United Kingdom.

Aim

To assess the incidence of rebleeding and review treatment outcomes in subjects with haemophilia with inhibitors enrolled in the phase 3 PERSEPT 1 clinical trial.

Methods

To treat mild/moderate bleeding episodes (BEs), subjects administered an initial 75 or 225µg/kg dose of eptacog beta, followed (if necessary) by additional 75µg/kg doses at predefined intervals until bleed control. This analysis used subject‐reported rebleeding to determine a rebleeding incidence for the first 24 h. Rebleeding through later timepoints was an exploratory, intention‐to‐treat analysis of bleed treatment data.

Results

Four hundred and sixty‐five BEs were analysed. Through 24 h, the proportion of rebleeds was 0% (initial 75µg/kg dose) and 0.5% (initial 225µg/kg dose). Through 48 h, the proportion of rebleeds was 3.2% (75µg/kg initial dose) and 5.6% (225µg/kg initial dose); the difference between initial dose strategies was not statistically significant. The majority of rebleeds were controlled with a single dose of eptacog beta and no subject who treated a rebleed required hospitalization.

Conclusion

Subjects with haemophilia with inhibitors who used eptacog beta to treat mild/moderate BEs experienced a low incidence of rebleeding. Rebleeds that did occur were effectively controlled with eptacog beta (median, one dose) without the need for hospitalization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHemorrhageFactor VIIaHemophilia BHumansRecombinant ProteinsAdolescentAdultMaleIncidenceYoung AdultRecurrenceMiddle AgedTreatment OutcomeChildFemale

Stichwörter der Autor:innen

efficacyeptacog betahaemophiliainhibitorsrebleeding incidencerecombinant FVIIa

Substanzen

Recombinant ProteinsFactor VIIarecombinant FVIIa

Autor:innen und Institutionen

  • Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Université Lyon, Lyon, France.
  • Hemophilia and Thrombosis Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.
  • University of California, Davis, Sacramento, California, USA.

ORCID-Profile: Yasmina Abajas, Manuel Carcao, Giancarlo Castaman, Victor Jiménez-Yuste, Magdalena Lewandowska, Johnny Mahlangu, Shannon Meeks, Wolfgang Miesbach, Michael Recht, Daniel Bonzo, Ian S Mitchell, Thomas A Wilkinson, Guy Young

Zitieren

APA

Dunn, A., Dargaud, Y., Abajas, Y., Carcao, M., Castaman, G., Giermasz, A., Hermans, C., Jiménez-Yuste, V., Lewandowska, M., Mahlangu, J., Meeks, S., Miesbach, W., Recht, M., Salinas, V., Chrisentery-Singleton, T., Bonzo, D., Mitchell, I. S., Wilkinson, T. A., & Young, G. (2025). Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia. https://doi.org/10.1111/hae.15109

Vancouver

Dunn A, Dargaud Y, Abajas Y, Carcao M, Castaman G, Giermasz A, et al. Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia. 2025. doi:10.1111/hae.15109

BibTeX
@article{Dunn2025,
  author = {Dunn, Amy and Dargaud, Yesim and Abajas, Yasmina and Carcao, Manuel and Castaman, Giancarlo and Giermasz, Adam and Hermans, Cédric and Jiménez-Yuste, Victor and Lewandowska, Magdalena and Mahlangu, Johnny and Meeks, Shannon and Miesbach, Wolfgang and Recht, Michael and Salinas, Vanessa and Chrisentery-Singleton, Tammuella and Bonzo, Daniel and Mitchell, Ian S and Wilkinson, Thomas A and Young, Guy},
  title = {Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.15109}
}
Kostenlos starten →